GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeStar Therapeutics Corp (OTCPK:GSTC) » Definitions » Cash Flow from Financing

GlobeStar Therapeutics (GlobeStar Therapeutics) Cash Flow from Financing : $0.20 Mil (TTM As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is GlobeStar Therapeutics Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, GlobeStar Therapeutics received $0.02 Mil more from issuing new shares than it paid to buy back shares. It received $0.03 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, GlobeStar Therapeutics earned $0.04 Mil on financial activities for the three months ended in Dec. 2023.


GlobeStar Therapeutics Cash Flow from Financing Historical Data

The historical data trend for GlobeStar Therapeutics's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeStar Therapeutics Cash Flow from Financing Chart

GlobeStar Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.22 0.68 0.33 0.20

GlobeStar Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.05 0.04 0.07 0.04

GlobeStar Therapeutics Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

GlobeStar Therapeutics's Cash from Financing for the fiscal year that ended in Sep. 2023 is calculated as:

GlobeStar Therapeutics's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlobeStar Therapeutics  (OTCPK:GSTC) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

GlobeStar Therapeutics's issuance of stock for the three months ended in Dec. 2023 was $0.02 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

GlobeStar Therapeutics's repurchase of stock for the three months ended in Dec. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

GlobeStar Therapeutics's net issuance of debt for the three months ended in Dec. 2023 was $0.03 Mil. GlobeStar Therapeutics received $0.03 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

GlobeStar Therapeutics's net issuance of preferred for the three months ended in Dec. 2023 was $0.00 Mil. GlobeStar Therapeutics paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

GlobeStar Therapeutics's cash flow for dividends for the three months ended in Dec. 2023 was $0.00 Mil. GlobeStar Therapeutics received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

GlobeStar Therapeutics's other financing for the three months ended in Dec. 2023 was $0.00 Mil. GlobeStar Therapeutics received $0.00 Mil on other financial activities.


GlobeStar Therapeutics Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of GlobeStar Therapeutics's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


GlobeStar Therapeutics (GlobeStar Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
719 Jadewin Avenue, Richland, WA, USA, 99352
GlobeStar Therapeutics Corp is a clinical-stage Pharmaceutical Company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.
Executives
James C Katzaroff director, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352
William J Farley director 468 ALBERN AVE, OCEANSIDE NY 11572
Robert Chicoski officer: CFO 145 NEWTON ROAD, HAVERHILL MA 01830
Alex K Blankenship director, officer: CEO, Pres., Secr., Treas. 14001 WALDEN RD., SUITE 600, MONTGOMERY TX 77356
Brent Atwood 10 percent owner 5000 RIVERSIDE DR STE100E, IRVING TX 75039
Bruce C Badeau director 770 S. POST OAK LN., STE. 360, HOUSTON TX 77056
Robert W Fryer director 1520 ENCLAVE, # 1208, HOUSTON TX 77077
Robert Federowicz director, officer: Interim CEO & Chairman 495 GRAND BLVD., SUITE 206, MIRAMAR BEACH FL 32550

GlobeStar Therapeutics (GlobeStar Therapeutics) Headlines

From GuruFocus

AngioSoma Moving Forward With Exciting New Products

By Marketwired Marketwired 03-09-2020